Breaking News, Collaborations & Alliances

Teva Terminates CureTech Agreements

Ends investment in cancer drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Teva Pharmaceutical Industries has terminated its collaboration with CureTech, Ltd. The companies were working together on CT-011, a humanized monoclonal antibody being developed as a treatment for hematological malignancies and solid tumors. Teva entered into agreements with CureTech in 2006 and plans to book a noncash charge of $109 million as a result of the impairment of its investment in CureTech.   “We are in the process of conducting a disciplined review of our pipeline. As we looke...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters